Hyperpolarized Xe129 ( DrugBank: - )

---

4 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	1
85	Idiopathic interstitial pneumonia	1
86	Pulmonary arterial hypertension	1
299	Cystic fibrosis	1

51. Scleroderma

---

Clinical trials : 525 /  Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05204355 (ClinicalTrials.gov)	May 1, 2022	10/1/2022	MRI for Screening and Monitoring Scleroderma ILD	MRI for Screening and Monitoring Systemic Sclerosis Interstitial Lung Disease	Scleroderma	Diagnostic Test: MRI;Drug: Hyperpolarized Xe129;Diagnostic Test: HRCT	University of Kansas Medical Center	Scleroderma Foundation	Recruiting	18 Years	N/A	All	42		United States

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04677426 (ClinicalTrials.gov)	May 1, 2022	16/12/2020	129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study	129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study	Idiopathic Pulmonary Fibrosis;Hypersensitivity Pneumonitis	Drug: Hyperpolarized Xe129	University of Kansas Medical Center	Duke University;Children's Hospital Medical Center, Cincinnati;Boehringer Ingelheim	Withdrawn	18 Years	N/A	All	0	Phase 2	NULL

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05339386 (ClinicalTrials.gov)	August 29, 2022	13/4/2022	Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension	Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Hyperpolarized Xe129	University of Kansas Medical Center	American Heart Association	Recruiting	18 Years	N/A	All	22		United States

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04624490 (ClinicalTrials.gov)	November 2, 2020	31/10/2020	Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease	Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease	Asthma;COPD;Interstitial Lung Disease;Cystic Fibrosis;Pulmonary Hypertension;Pulmonary Infection;Other Lung Disease	Drug: Hyperpolarized Xe129	Mario Castro, MD, MPH	NULL	Recruiting	3 Years	N/A	All	260	Phase 1	United States